Tisagenlecleucel
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Tisagenlecleucel |
| DrugBank ID | DB13881 |
| Brand Names (EU) | Kymriah |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 91.39% |
Approved Indication (EMA)
Kymriah is indicated for the treatment of: • Paediatric and young adult patients up to and including 25 years of age with B cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post transplant or in second or later relapse. • Adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) after two or more lines of systemic therapy. • Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | Crohn’s colitis | 91.39% | DL |
| 2 | multiple endocrine neoplasia | 91.34% | DL |
| 3 | idiopathic aplastic anemia | 89.69% | DL |
| 4 | adrenal gland hyperfunction | 88.34% | DL |
| 5 | HER2 positive breast carcinoma | 88.02% | DL |
| 6 | ankylosing spondylitis | 87.11% | DL |
| 7 | lymphoadenopathic mastocytosis with eosinophilia | 87.04% | DL |
| 8 | systemic mastocytosis | 87.00% | DL |
| 9 | Smouldering systemic mastocytosis | 86.83% | DL |
| 10 | rheumatoid vasculitis | 86.24% | DL |
| 11 | normal breast-like subtype of breast carcinoma | 85.85% | DL |
| 12 | progesterone-receptor positive breast cancer | 85.85% | DL |
| 13 | breast tumor luminal A or B | 85.64% | DL |
| 14 | hypermobility of coccyx | 85.64% | DL |
| 15 | polyarticular juvenile rheumatoid arthritis | 85.59% | DL |
| 16 | inflammatory spondylopathy | 85.54% | DL |
| 17 | multifocal choroiditis | 85.49% | DL |
| 18 | drug-induced osteoporosis | 85.45% | DL |
| 19 | progesterone-receptor negative breast cancer | 85.12% | DL |
| 20 | psoriasis | 85.06% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.